Citigroup
FDMT icon

Citigroup’s 4D Molecular Therapeutics FDMT Stock Holding History

Citigroup’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$921K Buy
69,212
+43,032
+164% +$419K ﹤0.01% 3514
2026
Q1 		$244K Buy
26,180
+13,521
+107% +$118K ﹤0.01% 3921
2025
Q4 		$94.9K Buy
12,659
+9,164
+262% +$93K ﹤0.01% 4347
2025
Q3 		$30.4K Sell
3,495
-19,301
-85% -$115K ﹤0.01% 4656
2025
Q2 		$84.6K Sell
22,796
-62,284
-73% -$219K ﹤0.01% 4492
2025
Q1 		$275K Sell
85,080
-8,541
-9% -$40.2K ﹤0.01% 4007
2024
Q4 		$521K Buy
93,621
+3,219
+4% +$25.3K ﹤0.01% 3791
2024
Q3 		$977K Buy
90,402
+7,592
+9% +$126K ﹤0.01% 3280
2024
Q2 		$1.74M Sell
82,810
-70,474
-46% -$1.77M ﹤0.01% 2457
2024
Q1 		$4.88M Buy
153,284
+111,976
+271% +$2.86M ﹤0.01% 1721
2023
Q4 		$837K Sell
41,308
-13,391
-24% -$176K ﹤0.01% 2979
2023
Q3 		$696K Sell
54,699
-3,458
-6% -$57.8K ﹤0.01% 2799
2023
Q2 		$1.05M Sell
58,157
-53,521
-48% -$985K ﹤0.01% 2813
2023
Q1 		$1.92M Buy
111,678
+85,862
+333% +$1.67M ﹤0.01% 2050
2022
Q4 		$573K Buy
25,816
+15,922
+161% +$246K ﹤0.01% 3067
2022
Q3 		$80K Sell
9,894
-2,343
-19% -$21.2K ﹤0.01% 4197
2022
Q2 		$85K Sell
12,237
-16,358
-57% -$159K ﹤0.01% 4296
2022
Q1 		$432K Sell
28,595
-54,577
-66% -$857K ﹤0.01% 3611
2021
Q4 		$1.82M Buy
83,172
+80,369
+2,867% +$1.97M ﹤0.01% 2697
2021
Q3 		$76K Buy
2,803
+1,218
+77% +$34.7K ﹤0.01% 4525
2021
Q2 		$38K Buy
1,585
+217
+16% +$6.64K ﹤0.01% 4942
2021
Q1 		$59K Buy
+1,368
New +$60.6K ﹤0.01% 4609

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Citigroup's FDMT Position: Q2 2026 in Review

Citigroup increased its 4D Molecular Therapeutics (FDMT) stake by 164% in Q2 2026, buying an estimated $419K and bringing the position to 69,212 shares worth $921K. The position accounts for ﹤0.01% of the portfolio, ranked #3514.

Citigroup first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $4.88M in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Citigroup held 69,212 shares of 4D Molecular Therapeutics worth $921K as of Q2 2026.
  • Citigroup bought 43,032 4D Molecular Therapeutics shares in Q2 2026, an estimated $419K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3514 holding.
  • Citigroup first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Citigroup's 4D Molecular Therapeutics position peaked at $4.88M in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.